INTENSIVE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY GERM CELL TUMORS EMPLOYING HIGH-DOSE CARBOPLATIN, ETOPOSIDE, AND THIOTEPA WITH AUTOLOGOUS BONE MARROW RESCUE FOR PATIENTS 15 TO 60 YEARS OF AGE
OBJECTIVES: I. Determine the response rate, overall survival, and disease-free survival of
patients with refractory or relapsed germ cell carcinoma treated with high-dose induction
chemotherapy comprising carboplatin and etoposide followed by autologous bone marrow or
peripheral blood stem cell rescue.
OUTLINE: Autologous peripheral blood stem cells (PBSC) or bone marrow is harvested. Patients
receive carboplatin IV continuously and etoposide IV over 1 hour on days -5 through -3.
Autologous PBSC or bone marrow is reinfused on day 0.
PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study.
Interventional
Primary Purpose: Treatment
Thomas R. Klumpp, MD
Study Chair
Fox Chase Cancer Center
United States: Federal Government
CDR0000078063
NCT00002508
November 1990
September 2001
Name | Location |
---|---|
Temple University Cancer Center | Philadelphia, Pennsylvania 19140 |